Ascletis Pharma (HKG:1672) plans to repurchase up to HK$300 million of its shares on the open market under a general mandate approved by shareholders.
The shares may be canceled, sold, transferred or held as treasury, as deemed appropriate by the board, according to a Tuesday Hong Kong bourse filing.